Malaysia Brain Cancer Therapeutics Market

Malaysia Brain Cancer Therapeutics Market Executive Summary

Malaysia Brain Cancer Therapeutics Market valued at $4 Mn in 2022, projected to reach $8 Mn by 2030 with a 10.8% CAGR.

The abnormal growth of brain cells serves as an indicator of brain cancer, wherein these cells display characteristics that can be either malignant (cancerous) or benign (non-cancerous). Although the precise cause of brain cancer remains unclear, recognized risk factors encompass exposure to ionizing radiation and a family history of brain tumors. Common symptoms associated with a brain tumor consist of headaches, gradual sensory decline, balance issues, speech impediments, and hearing difficulties. The presentation of these symptoms varies depending on factors like the tumor’s size, location, and growth rate. Treatment strategies for brain cancer are determined by the tumor’s type, location, and size, with frequently employed methods including radiosurgery, chemotherapy, radiotherapy, surgery, and the utilization of carmustine implants.

In 2023, the prevalence of brain cancer in Malaysia was 1.26 cases per 100,000 population annually. Brain tumors were the 11th most prevalent cancer in men and the 13th most common in women in the nation, accounting for about 2% of all cancer cases. A total of 128,018 instances, or 54,044 female cases and 73,974 male cases, were judged to be the 5-year common cases. This translates to a prevalence rate of almost 398 cases per 100,000 individuals, underscoring the significance of brain cancer for the Malaysian population as well as the ongoing need to focus on its detection, management, and prevention.

GlaxoSmithKline (GSK) began brain cancer clinical trials with Zejula, a medication that was first intended to treat ovarian cancer. The purpose of this early-stage experiment is to evaluate Zejula's effectiveness in treating patients with recurrent brain cancer and newly diagnosed glioblastoma. Sumitomo Pharma Oncology has simultaneously received an Orphan Drug Designation for DSP-0390, an experimental Emopamil-binding Protein (EBP) Inhibitor that is meant to treat brain cancer. DSP-0390 is being evaluated for safety and efficacy in patients with glioblastoma multiforme (GBM), a high-grade glioma. This clinical trial is now in its Phase 1 phase. These findings highlight continued attempts to improve brain cancer therapeutic choices by employing cutting-edge medications and modes of care.

Market Dynamics

Market Growth Drivers

Increasing Incidence Rates: An increase in brain cancer incidence fuels the need for medications used in therapy. Effective pharmacological therapies may be required if brain cancer incidence rises due to factors like population expansion, aging demographics, and lifestyle changes.

Increasing Healthcare Awareness: Growing awareness about the importance of early detection, regular screenings, and access to advanced treatments for brain cancer can drive patient demand for effective pharmaceutical solutions. Increased public awareness often leads to a proactive approach to healthcare, influencing market growth.

Advancements in Treatment Options: The development of innovative medicines for brain-related disorders and technological advances in the healthcare industry are improving the effectiveness of treatments, which in turn is driving market expansion. The introduction of novel and efficacious treatments frequently results in a surge in the demand for these therapies. As the market expands, it attracts further investment, fostering a cycle of innovation, demand, and growth within the healthcare industry.

Market Restraints

Regulatory Hurdles: The strict regulations and approval processes could create challenges for the creation and release of new medications for treating brain cancer, which may result in delays in their availability.

High Cost of Treatment: The substantial costs associated with advanced treatments such as targeted drugs and immunotherapies pose a financial challenge for both patients and the healthcare system. Financial hardship may be exacerbated by access to these expensive treatments being hampered by complex payment processes or inadequate insurance coverage. As a result, gaps in treatment availability due to socioeconomic reasons could appear, raising ethical questions about the equitable distribution of healthcare.

Limited Efficacy of Current Treatments: The effectiveness of current treatments for brain cancer might be constrained, emphasizing the necessity for groundbreaking innovations to markedly enhance patient outcomes. This constraint could potentially influence the market prospects of presently available drugs.

Healthcare Policies and Regulatory Landscape

The National Pharmaceutical Regulating Agency (NPRA), the primary regulatory authority overseeing pharmaceutical treatments in Malaysia, operates under the Ministry of Health. NPRA ensures the quality, safety, and effectiveness of pharmaceutical products by managing processes like medication registration, approval, and post-market surveillance. Strict enforcement of Good Manufacturing Practice (GMP) guidelines is integral to maintaining consistent pharmaceutical quality during production. The sale and distribution of therapeutic drugs, along with other pharmacy-related activities, are governed by the Pharmacy Practice and Poisons Act of 1952. Ongoing evaluation of the safety and efficacy of approved medicines is conducted through continuous post-market surveillance. Essential medications that must meet specific standards are listed on the National Essential Medicines List. Additionally, Malaysia explores the application of Health Technology Assessment to evaluate the impact of emerging health technologies, including medications.

Competitive Landscape

Key Players

• Merck & Co
• Amgen
• Roche
• Pfizer
• Teva Pharmaceutical
• Karyopharm Therapeutics
• Novartis
• AstraZeneca
• Bristol Myers Squibb
• Eli Lilly